Barclays raised the firm’s price target on Guardant Health (GH) to $85 from $70 and keeps an Overweight rating on the shares following the earnings report. Guardant is “firing on all cylinders,” with a broad-based beat across oncology, biopharma and screening, the analyst tells investors in a research note. The firm sees “plenty of opportunities” for the company’s growth trajectory to continue into 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health Reports Strong Q3 2025 Growth
- Guardant Health: Strong Performance and Growth Potential Drive Buy Rating
- Closing Bell Movers: Meta sinks, Alphabet jumps after earnings
- Guardant Health reports Q3 EPS (39c), consensus (49c)
- Guardant Health raises FY25 revenue view to $965M-$970M from $915M-$925M